Search

Your search keyword '"Touw, Daan J."' showing total 672 results
Start Over Author "Touw, Daan J." Language english
672 results on '"Touw, Daan J."'

4. Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study

Author

van der Kleij, Maud B. A., Guchelaar, Niels A. D., Meertens, Marinda, Westerdijk, Kim, Giraud, Eline L., Bleckman, Roos F., Groenland, Stefanie L., van Eerden, Ruben A. G., Imholz, Alex L. T., Vulink, Annelie J. E., Otten, Hans-Martin, Fiebrich-Westra, Helle-Brit, Lubberman, Floor J. E., Desar, Ingrid M. E., Moes, Dirk-Jan A. R., Touw, Daan J., Koolen, Stijn L. W., Gelderblom, Hans, Reyners, An K. L., van Erp, Nielka P., Mathijssen, Ron H. J., Huitema, Alwin D. R., and Steeghs, Neeltje

Published
2024
Full Text
View/download PDF

8. Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort

Author

Meertens, Marinda, Giraud, Eline L., van der Kleij, Maud B. A., Westerdijk, Kim, Guchelaar, Niels A. D., Bleckman, Roos F., Rieborn, Amy, Imholz, Alex L. T, Otten, Hans-Martin, Vulink, Annelie, Los, Maartje, Hamberg, Paul, van der Graaf, Winette T. A., Gelderblom, Hans, Moes, Dirk Jan A. R., Broekman, K. Esther, Touw, Daan J., Koolen, Stijn L. W., Mathijssen, Ron H. J., Huitema, Alwin D. R., van Erp, Nielka P., Desar, Ingrid M. E., and Steeghs, Neeltje

Published
2024
Full Text
View/download PDF

11. Muscle Mass, Muscle Strength, and Health-Related Quality of Life in Kidney Transplant Recipients: Results of the TransplantLines Biobank and Cohort Study

Author

Annema, Coby, Blokzijl, Hans, Bodewes, Frank AJA., de Boer, Marieke T., Damman, Kevin, de Borst, Martin H., Diepstra, Arjan, Dijkstra, Gerard, Doorenbos, Caecilia SE., Eisenga, Michele F., Erasmus, Michiel E., Gan, C Tji, Hak, Eelko, Hepkema, Bouke G., Leuvenink, Henri GD., Lexmond, Willem S., de Meijer, Vincent E., Niesters, Hubert GM., Joost van Pelt, L., Pol, Robert A., Porte, Robert J., Ranchor, Adelita V., Stephan F Sanders, Jan, Siebelink, Marion J., Slart, Riemer JHJA., Touw, Daan J., te Velde-Keyzer, Charlotte A., van den Heuvel, Marius C., van Leer-Buter, Coretta, van Londen, Marco, Verschuuren, Erik AM., Vos, Michel J., Weersma, Rinse K., Knobbe, Tim J., Lenis, Gijs M.M., van der Vossen, Dirk A.J., Wentink, Jory, Kremer, Daan, Quint, Evelien E., Gomes-Neto, Antonio W., Dullaart, Robin P.F., Berger, Stefan P., Franssen, Casper F.M., Bakker, Stephan.J.L., and Post, Adrian

Published
2025
Full Text
View/download PDF

15. Iron deficiency, anemia, and patient-reported outcomes in kidney transplant recipients

Author

Ranchor, Adelta V., Gomes Neto, Antonio W., Diepstra, Arjan, Hepkema, Bouke G., Tji Gan, C., Doorenbos, Caecilia S.E., te Velde-Keyzer, Charlotte A., van Leer-Buter, Coretta, Touw, Daan J., Hak, Eelko, Verschuuren, Erik A.M., Bodewes, Frank A.J.A., Klont, Frank, Dijkstra, Gerard, Nieuwenhuis-Moeke, Gertrude J., Blokzijl, Hans, Leuvenink, Henri G.D., Niesters, Hubert G.M., Cas Swarte, J., Sanders, Jan Stephan F., Damman, Kevin, Joost van Pelt, L., van Londen, Marco, de Boer, Marieke T., Siebelink, Marion J., van den Heuvel, Marius C., Vos, Michel J., Erasmus, Michiel E., Douwes, Rianne M., Slart, Riemer J.H.J.A., Weersma, Rinse K., Pol, Robert A., Porte, Robert J., de Meijer, Vincent E., Lexmond, Willem S., Kremer, Daan, Knobbe, Tim J., Vinke, Joanna Sophia J., Groothof, Dion, Post, Adrian, Annema, Coby, Abrahams, Alferso C., van Jaarsveld, Brigit C., de Borst, Martin H., Berger, Stefan P., Bakker, Stephan J.L., and Eisenga, Michele F.

Published
2024
Full Text
View/download PDF

22. Central Body Fat Distribution and Kidney Function after Living Kidney Donation

Author

Westenberg, Lisa B., Pol, Robert A., van der Weijden, Jessica, de Borst, Martin H., Bakker, Stephan J.L., van Londen, Marco, Annema, Coby, Berger, Stefan P., Blokzijl, Hans, Bodewes, Frank A.J.A., de Boer, Marieke T., Damman, Kevin, de Borst, Martin H., Diepstra, Arjan, Dijkstra, Gerard, Douwes, Rianne M., Doorenbos, Caecilia S.E., Eisenga, Michele F., Erasmus, Michiel E., Gan, C. Tji, Gomes Neto, Antonio W., Hak, Eelko, Hepkema, Bouke G., van den Heuvel, Marius C., Klont, Frank, Knobbe, Tim J., Kremer, Daan, van Leer-Buter, Coretta, Leuvenink, Henri G.D., van Londen, Marco, Lexmond, Willem S., de Meijer, Vincent E., Niesters, Hubert G.M., Nieuwenhuis-Moeke, Gertrude J., Joost van Pelt, L., Pol, Robert A., Porte, Robert J., Ranchor, Adelta V., Sanders, Jan Stephan F., Siebelink, Marion J., Slart, Riemer J.H.J.A., Swarte, J. Cas, Touw, Daan J., te Velde-Keyzer, Charlotte A., Verschuuren, Erik A.M., Vos, Michel J., Weersma, Rinse K., and Bakker, Stephan J.L.

Published
2024
Full Text
View/download PDF

25. Proton Pump Inhibitor Use, Fatigue, and Health-Related Quality of Life in Kidney Transplant Recipients: Results From the TransplantLines Biobank and Cohort Study

Author

Blokzijl, Hans, Bodewes, Frank A.J.A., de Boer, Marieke T., Damman, Kevin, de Borst, Martin H., Diepstra, Arjan, Dijkstra, Gerard, Doorenbos, Caecilia S.E., Erasmus, Michiel E., Gan, C. Tji, Hak, Eelko, Hepkema, Bouke G., Leuvenink, Henri G.D., Lexmond, Willem S., de Meijer, Vincent E., Niesters, Hubert G.M., van Pelt, L. Joost, Pol, Robert A., Porte, Robert J., Ranchor, Adelta V., Sanders, Jan Stephan F., Siebelink, Marion J., Slart, Riemer J.H.J.A., Touw, Daan J., van den Heuvel, Marius C., van Leer-Buter, Coretta, van Londen, Marco, Verschuuren, Erik A.M., Vos, Michel J., Weersma, Rinse K., Knobbe, Tim J., Kremer, Daan, Douwes, Rianne M., Eisenga, Michele F., Gomes-Neto, António W., Annema, Coby, Swarte, J. Casper, Klont, Frank, Navis, Gerjan, Berger, Stefan P., and Bakker, Stephan J.L.

Published
2023
Full Text
View/download PDF

28. Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan

Author

Hulshof, Emma C., Deenen, Maarten J., Nijenhuis, Marga, Soree, Bianca, de Boer-Veger, Nienke J., Buunk, Anne-Marie, Houwink, Elisa J. F., Risselada, Arne, Rongen, Gerard A. P. J. M., van Schaik, Ron H. N., Touw, Daan J., van der Weide, Jan, van Westrhenen, Roos, Deneer, Vera H. M., Guchelaar, Henk-Jan, and Swen, Jesse J.

Published
2023
Full Text
View/download PDF

32. Plasma Lead Concentration and Risk of Late Kidney Allograft Failure: Findings From the TransplantLines Biobank and Cohort Studies

Author

Damman, Kevin, de Meijer, Vincent E., Porte, Robert J., de Boer, Marieke T., Leuvenink, Henri G.D., Pol, Robert A., Annema, Coby, Ranchor, Adelita V., Siebelink, Marion J., Lexmond, Willem S., Hepkema, Bouke G., Joost van Pelt, L., Gan, C. Tji, Verschuuren, Erik A.M., Bodewes, Frank A.J.A., Dijkstra, Gerard, Blokzijl, Hans J., Niesters, Bert H.G.M., Sanders, Jan-Stephan F., Grootjans, Heleen, Douwes, Rianne M., Eisenga, Michele F., Gomes-Neto, António W., Kremer, Daan, Slart, Riemer H.J.A., Erasmus, Michiel E., van Leer-Buter, Coretta, van Londen, Marco, Timens, Wim, Diepstra, Arjan, van den Heuvel, Marius C., Knobbe, Tim J., Schutten, Joëlle C., Swarte, Cas, Weersma, Rinse K., Touw, Daan J., Heiner-Fokkema, Rebecca, Vos, Michel, Klont, Frank, Hak, Eelko, Sotomayor, Camilo G., Giubergia, Flavia, Groothof, Dion, Ferreccio, Catterina, Nolte, Ilja M., Navis, Gerjan J., Gomes-Neto, Antonio W., Rodrigo, Ramón, and Bakker, Stephan J.L.

Published
2022
Full Text
View/download PDF

33. Clinical and Biochemical Factors Associated with Infliximab Pharmacokinetics in Paediatric Patients with Inflammatory Bowel Disease.

Author

Wang, Ka Yu, Heikal, Omnia Salah, van Rheenen, Patrick F., Touw, Daan J., Bourgonje, Arno R., and Mian, Paola

Abstract

Monitoring infliximab (IFX) concentrations is crucial for optimizing IFX therapy in children with inflammatory bowel diseases (IBDs) who show low response rates due to inadequate drug exposure. Substantial variation occurs in IFX trough concentrations in paediatric patients. Objectives: This study aimed to investigate IFX pharmacokinetics (PK) in children with IBD during both the induction phase and maintenance phases and to identify covariates associated with IFX PK. Methods: This single-centre retrospective cohort study was conducted at an academic children's hospital. Data was extracted from paediatric IBD patients receiving IFX between January 2018 and October 2023 and included demographic-, clinical- and laboratory parameters collected from electronic health records. Linear mixed model analysis was performed to investigate associations between these parameters and IFX trough concentrations. Target attainment [≥15 μg/mL in induction or 5–10 μg/mL in maintenance phase] of the IFX dosing regimens was evaluated. Results and Conclusions: A total of 115 children (417 unique IFX concentrations) were included. Multivariate analysis revealed significant positive associations between IFX and albumin concentrations (β = 0.388, p = 0.010) and IFX concentrations with dose (β = 6.534, p < 0.001), and an inversion association between IFX concentrations and treatment phase (β = −4.922, p < 0.001). During the induction and maintenance phases, 57.2% and 30.6% of IFX concentrations were subtherapeutic, respectively. A systematic search of studies investigating factors influencing IFX concentrations was concurrently performed. Our findings were critically compared against existing literature to assess relevant clinical and biochemical determinants of IFX PK in children with IBD. Our findings highlight the need for personalized dosing strategies in pediatric IBD patients, particularly during the induction phase. By implementing therapeutic drug monitoring (TDM) and considering clinical and biochemical factors, clinicians can implement more personalized strategies, potentially improving treatment efficacy and reducing the risk of treatment failure or adverse effects. This approach could lead to better target attainment, potentially enhancing clinical outcomes and minimizing premature switching to other therapies. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

47. Urine cotinine versus self-reported smoking and the risk of chronic kidney disease.

Author

Kunutsor, Setor K, Dey, Richard S, Touw, Daan J, Bakker, Stephan J L, and Dullaart, Robin P F

Subjects
DISEASE risk factors, CHRONIC kidney failure, COTININE, KIDNEY development, SMOKING
Abstract

Background and hypothesis Evidence on the role of smoking in the development of chronic kidney disease (CKD) has mostly relied on self-reported smoking status. We aimed to compare the associations of smoking status as assessed by self-reports and urine cotinine with CKD risk. Methods Using the PREVEND prospective study, smoking status was assessed at baseline using self-reports and urine cotinine in 4333 participants (mean age, 52 years) without a history of CKD at baseline. Participants were classified as never, former, light current, and heavy current smokers according to self-reports and comparable cutoffs for urine cotinine. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated for CKD. Results The percentages of self-reported and cotinine-assessed current smokers were 27.5% and 24.0%, respectively. During a median follow-up of 7.0 years, 593 cases of CKD were recorded. In analyses adjusted for established risk factors, the HRs (95% CI) of CKD for self-reported former, light current, and heavy current smokers compared with never smokers were 1.17 (0.95–1.44), 1.48 (1.10–2.00), and 1.48 (1.14–1.93), respectively. On further adjustment for urinary albumin excretion (UAE), the HRs (95% CI) were 1.07 (0.87–1.32), 1.26 (0.93–1.70), and 1.20 (0.93–1.57), respectively. For urine cotinine-assessed smoking status, the corresponding HRs (95% CI) were 0.81 (0.52–1.25), 1.17 (0.92–1.49), and 1.32 (1.02–1.71), respectively, in analyses adjusted for established risk factors plus UAE. Conclusion Self-reported current smoking is associated with increased CKD risk, but dependent on UAE. The association between urine cotinine-assessed current smoking and increased CKD risk is independent of UAE. Urine cotinine-assessed smoking status may be a more reliable risk indicator for CKD incidence than self-reported smoking status. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Efficacy and safety of low‐dose digoxin in patients with heart failure. Rationale and design of the DECISION trial.

Author

van Veldhuisen, Dirk J., Rienstra, Michiel, Mosterd, Arend, Alings, A. Marco, van Asselt, Antoinette D.J., Bouvy, Marcel L, Tijssen, Jan G.P., Schaap, Jeroen, van der Wall, Ernst E., Voors, Adriaan A., Boorsma, Eva M., Lok, Dirk J.A., Crijns, Harry J.G.M., Schut, Astrid, Vijver, Marlene A.T., Voordes, Geert H.D., de Vos, Agaath H., Maas‐Soer, Ester L., Smit, Nicoline W., and Touw, Daan J.

Subjects
VENTRICULAR ejection fraction, DIGOXIN, HEART failure patients, ATRIAL fibrillation, HEART failure
Abstract

Aims: Digoxin is the oldest drug in cardiovascular (CV) medicine, and one trial conducted >25 years ago showed a reduction in heart failure (HF) hospitalizations but no effect on mortality. However, later studies suggested that the dose of digoxin used in that trial (and other studies) may have been too high. The DECISION (Digoxin Evaluation in Chronic heart failure: Investigational Study In Outpatients in the Netherlands) trial will examine the efficacy and safety of low‐dose digoxin in HF patients with reduced or mildly reduced left ventricular ejection fraction (LVEF) with a background of contemporary HF treatment. Methods: The DECISION trial is a randomized, double‐blind, parallel‐group, placebo‐controlled event‐driven outcome trial which will investigate the efficacy and safety of low‐dose digoxin in patients with chronic HF and LVEF <50%. Both patients with sinus rhythm and atrial fibrillation will be enrolled and will be randomized (1:1) to low‐dose digoxin or matching placebo. To maintain a target serum digoxin concentration of 0.5–0.9 ng/ml, dose adjustments are made throughout follow‐up based on serum digoxin measurements with dummy values for the placebo group. The primary endpoint is a composite of CV mortality and total HF hospitalizations or total urgent hospital visits for worsening HF, and all endpoints are adjudicated blindly by a Clinical Event Committee. The estimated sample size was 982 patients who will be followed for a median of 3 years, and in December 2023 enrolment was completed after 1002 patients. Conclusions: The DECISION trial will provide important evidence regarding the effect of (low‐dose) digoxin on CV mortality and total HF hospitalizations and urgent hospital visits when added to contemporary HF treatment of patients with reduced or mildly reduced LVEF. Clinical Trial Registration: ClinicalTrials.gov identifier: NCT03783429. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models.

Author

Heikal, Omnia Salah, van Rheenen, Patrick F., Touw, Daan J., Kosterink, Jos G. W., Maurer, Marina, Koomen, Jeroen V., Chelle, Pierre, and Mian, Paola

Subjects
INFLAMMATORY bowel diseases, PHARMACOKINETICS, INFLIXIMAB, NECROSIS, PEDIATRICS
Abstract

Aims: Use of infliximab (IFX) has improved outcomes in children with inflammatory bowel disease (IBD). However, a proportion of patients does not respond to IFX or loses response over time. Population pharmacokinetic (PopPK) modelling is a promising approach for IFX dose optimization, but with the increasing number of PopPK models in literature, model evaluation is essential. The aims of this study are: (i) to validate the predictive performance of existing IFX PopPK models using a cohort of children with IBD; and (ii) to perform a Bayesian estimation of the most suitable model to predict the next IFX concentrations. Methods: PubMed was searched for IFX PopPK models in children. Selected models were rebuilt and analysed using R. Model performance was assessed through goodness‐of‐fit‐plots, residuals against time, prediction error and prediction‐corrected visual predictive checks. The validation cohort consisted of 73 children with IBD who were treated with IFX in our centre between 2017 and 2023 (340 IFX measurements). Results: We identified 9 PopPK models. Model bias for individual predicted values ranged from −9.29% to 8.01% compared to bias for population predicted values. The model by Vande Casteele et al. demonstrated superior performance (individual predicted bias 2.13, population predicted bias −6.11); upon Bayesian estimation, it predicted induction trough levels with median error of 12.95% but had a median error of −69% predicting maintenance concentrations. Conclusion: The model by Vande Casteele et al. displayed superior performance in initial evaluations but had a high error in estimating next IFX levels and can only be used in practice to predict induction levels. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results